The complaint
Pfizer Inc. v. Sun Pharmaceutical Industries Limited, No. 1:26-cv-01270 (D. Del.), is a 28-page complaint for patent infringement and declaratory judgment of patent infringement filed October 1, 2026. It is ECF No. 1. The plaintiffs are Pfizer Inc., PF PRISM IMB B.V., PF PRISM Holdings B.V., Pfizer Asia Manufacturing Pte Ltd, Pfizer Ireland Pharmaceuticals Unlimited Company, and Pfizer Ireland PFE Holding 1 LLC. The complaint refers to them together as Pfizer. The defendant is Sun Pharmaceutical Industries Limited.
The complaint describes Pfizer Inc. as a corporation organized under the laws of Delaware, with its principal place of business in New York, New York. It describes PF PRISM IMB B.V. as a Dutch private limited company with its registered seat in Rotterdam, the Netherlands, and a business address in Capelle aan den IJssel, the Netherlands. It describes PF PRISM Holdings B.V. as a Dutch private limited liability company with its corporate seat in Rotterdam, the Netherlands, and its registered office in Capelle aan den IJssel, the Netherlands. It describes Pfizer Asia Manufacturing Pte Ltd as a corporation organized under the laws of Singapore, and Pfizer Ireland Pharmaceuticals Unlimited Company, formerly known as Pfizer Ireland Pharmaceuticals, as a private unlimited liability company organized under the laws of Ireland, and gives its address as Ringaskiddy, Ireland. It describes Pfizer Ireland PFE Holding 1 LLC as a Delaware limited liability company with offices in New York, New York. The complaint says Pfizer Inc. is the ultimate parent company of each of the other plaintiffs. It alleges, on information and belief, that Sun is a corporation organized under the laws of India, with its principal place of business in Mumbai, India. It alleges, on information and belief, that Sun develops, manufactures, markets, distributes, imports, offers for sale, and/or sells generic pharmaceutical products throughout the United States, including in Delaware.
LORBRENA
The complaint says Pfizer holds NDA No. 210868 for LORBRENA, which the FDA approved on November 2, 2018, and that Pfizer markets and sells products that are the subject of that application in the United States under the brand name LORBRENA. It says the FDA granted seven years of orphan-drug exclusivity, which it identifies as ODE-349, under 21 U.S.C. § 360cc(a) and 21 C.F.R. § 316.31(a), and that the exclusivity expires on March 3, 2028. It says LORBRENA is indicated for the "treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test." It says the active ingredient is lorlatinib, a kinase inhibitor, gives the molecular formula of the anhydrous form as C21H19FN6O2 and the molecular weight as 406.41 Daltons, and says lorlatinib has in vitro activity against, among other things, ALK and ROS1. It says the recommended dosage is 100 mg orally once daily, with or without food, until disease progression or unacceptable toxicity, and that dose reductions to 75 mg and 50 mg are permitted.
What the patents cover
The complaint asserts U.S. Patents 8,680,111, 10,420,749, 11,020,376, and 11,299,500. It says that, pursuant to 21 U.S.C. § 355(b)(1) and the regulations the FDA has promulgated under that section, the patents are listed in the Orange Book for LORBRENA. It says Pfizer owns each patent, that PF PRISM IMB B.V. is the exclusive licensee of each, that PF PRISM IMB B.V. conveyed rights under each patent to PF PRISM Holdings B.V., that PF PRISM Holdings B.V. conveyed rights under each patent to Pfizer Asia Manufacturing Pte Ltd and Pfizer Ireland Pharmaceuticals Unlimited Company, and that Pfizer Ireland PFE Holding 1 LLC holds rights under each patent.
U.S. Patent 8,680,111, titled "Macrocyclic Derivatives for the Treatment of Diseases," issued March 25, 2014. The complaint says the patent is scheduled to expire on March 5, 2033, subject to any applicable extension or exclusivity. The complaint quotes claim 8. Claim 8 covers the compound of claim 1 that is (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile, or a pharmaceutically acceptable salt of that compound. The complaint identifies that compound as lorlatinib.
U.S. Patent 10,420,749, titled "Crystalline Form of Lorlatinib Free Base," issued September 24, 2019. The complaint says the patent is scheduled to expire on July 27, 2036, subject to any applicable extension or exclusivity. Claim 1 covers a crystalline form of lorlatinib free base having a powder X-ray diffraction pattern comprising peaks at 2-theta values of 9.6, 10.1, and 16.2, plus or minus 0.2.
U.S. Patent 11,020,376, titled "Crystalline Form of Lorlatinib Free Base," issued June 1, 2021. The complaint says the patent is scheduled to expire on July 27, 2036, subject to any applicable extension or exclusivity. Claim 1 covers a solid dosage form of lorlatinib free base, which the claim calls Form 7, wherein the dosage form has a powder X-ray diffraction pattern comprising peaks at 2-theta values of 9.6, 10.1, and 16.2, plus or minus 0.2.
U.S. Patent 11,299,500, titled "Crystalline Form of Lorlatinib Free Base Hydrate," issued April 12, 2022. The complaint says the patent is scheduled to expire on October 4, 2038, subject to any applicable extension or exclusivity. Claim 1 covers a crystalline form of lorlatinib free base hydrate having a powder X-ray diffraction pattern comprising peaks at 2-theta values of 8.8, 9.7, 17.6, and 18.8, plus or minus 0.2.
The ANDA and the notice letter
The complaint says the action arises out of Sun's filing, or causing to be filed, of ANDA No. 219998, seeking approval to market generic versions of LORBRENA tablets, 25 mg and 100 mg, before the asserted patents expire. It alleges, on information and belief, that Sun submitted ANDA No. 219998 under 21 U.S.C. § 355(j), seeking FDA approval to engage in the commercial manufacture, use, offer for sale, or sale in the United States, and/or importation into the United States, of lorlatinib tablets, 25 mg and 100 mg, before the patents expire. It says Sun sent Pfizer a notice letter dated August 17, 2026, and that Pfizer received the letter on August 18, 2026. It says the letter gave notice that the ANDA contains a certification under 21 U.S.C. § 355(j)(2)(A)(vii)(IV), stated that the FDA assigned ANDA No. 219998 to Sun, and identified the proposed product as "Lorlatinib Tablets 25 mg, 100 mg." It says the letter purported to contain a detailed statement of the factual and legal bases for Sun's certification that the four patents are invalid, unenforceable, and/or will not be infringed.
The complaint says the notice letter purported to contain an offer of confidential access to certain portions of ANDA No. 219998, and that the letter did not include evidence supporting Sun's assertion that the proposed product does not infringe. It says that on September 8, 2026, Pfizer responded that Sun's proposed terms were overly restrictive, unduly burdensome, and did not comply with 21 U.S.C. § 355(j)(5). It says Pfizer told Sun that the offer did not permit access by in-house counsel and did not make clear that Pfizer would be permitted to engage experts to assist counsel. It also says the offer limited access to unspecified "certain information," did not provide Pfizer the opportunity to test the ANDA product, and prevented counsel from representing any party in patent prosecution relating to lorlatinib tablets and any work before or involving the FDA relating to lorlatinib tablets. It says Pfizer proposed revisions that, among other things, would permit in-house counsel and three experts to have access to Modules 1, 2, and 3, and that Pfizer requested samples of the ANDA products and of the active pharmaceutical ingredient used to manufacture them, for infringement testing.
The complaint says that on September 15, 2026, Sun rejected many of the proposed revisions, that Pfizer wrote again on September 23, 2026, and that Sun responded on September 28, 2026 and restated many of the positions in its September 15 letter. It says the parties reached an impasse on September 29, 2026, due in part to Sun's refusal to provide ANDA product samples and access for in-house counsel. It says the samples would permit powder X-ray diffraction, Raman spectroscopy, and solid-state NMR testing, and that Pfizer requires, for example, a powder X-ray diffraction expert for testing related to claims 1 through 6 of the '749 patent, a Raman spectroscopy expert for claims 7 through 10, and a solid-state NMR expert for claims 13 through 20. It says Pfizer is commencing the action within 45 days of receiving the notice letter, the period set by 21 U.S.C. § 355(j)(5)(B)(iii). The ANDA supplemental information entry on the docket lists February 18, 2029 as the thirty-month stay deadline.
Jurisdiction and venue
The complaint says the action arises under the patent laws, 35 U.S.C. §§ 100 et seq., and the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202, and alleges subject-matter jurisdiction under 28 U.S.C. §§ 1331, 1338(a), and 2201-02. It alleges, upon information and belief, personal jurisdiction because Sun has purposely availed itself of the privilege of doing business in Delaware, directly or indirectly through its subsidiaries, agents, and/or alter egos; maintains pervasive, continuous, and systematic contacts with Delaware, including the marketing, distribution, and/or sale of generic pharmaceutical products there; derives substantial revenue from the sale of its products in Delaware; and intends, directly or indirectly, to market, sell, or distribute the ANDA products in Delaware. It also says the court has personal jurisdiction because Sun has availed itself of Delaware by previously consenting to personal jurisdiction and asserting counterclaims there, citing, among other cases, Nos. 25-1170-CFC, 25-423-RGA, 24-1208-RGA, 24-1014-CFC, 25-767-CFC, 24-789-JLH, 24-726-MN, 23-1459-CFC, 23-795-RGA, 20-988-RGA, and 21-1573-CFC. In the alternative, it alleges jurisdiction under Federal Rule of Civil Procedure 4(k)(2). It alleges that venue is proper under 28 U.S.C. § 1391(c)(3) because Sun is a foreign corporation and may be sued in any judicial district where it is subject to personal jurisdiction.
The eight counts
The First Cause of Action is infringement of the '111 patent. The complaint alleges that Sun has infringed that patent under 35 U.S.C. § 271(e)(2)(A) by submitting the ANDA with a Paragraph IV certification and seeking FDA approval before the patent expires. It alleges, on information and belief, that Sun submitted the ANDA or caused it to be submitted and continues to seek approval, that the ANDA seeks approval to manufacture, use, offer for sale, sell, and/or import the products before the patent expires, and that the products infringe at least claim 8. It alleges, on information and belief, that if the ANDA is approved, the manufacture, use, offer for sale, sale, and/or importation of the products would directly infringe one or more claims, that Sun and its affiliates would immediately make, sell, offer for sale, or otherwise distribute the products in the United States, including in Delaware, and that Sun's label is substantially identical to the LORBRENA label in all material respects and directs and actively encourages doctors to administer, and patients to take, the products in a manner that will infringe. It alleges, on information and belief, that Sun has acted with full knowledge of the patent and without a reasonable basis for believing that manufacture, use, or sale would not infringe, and that Sun lacks any basis for believing the product is a staple article or commodity of commerce suitable for substantial non-infringing use. It says Sun's detailed statement does not dispute that the products will infringe, contribute to the infringement of, or induce the infringement of the '111 patent, except to the extent the patent is found invalid.
The Second Cause of Action is a declaratory judgment of infringement of the '111 patent under 28 U.S.C. §§ 2201 and 2202. It alleges, on information and belief, that if the ANDA is approved, Sun and its affiliates will directly infringe one or more claims under at least 35 U.S.C. § 271(a), that health care professionals or patients who use the products will directly infringe under at least § 271(a), and that Sun knows and intends that use and will therefore contribute to or induce infringement under § 271(b) and (c). It alleges an actual, substantial, and justiciable controversy, and it alleges that the case is exceptional and that Pfizer is entitled to attorneys' fees under 35 U.S.C. § 285.
The Third Cause of Action is infringement of the '749 patent, the Fifth Cause of Action is infringement of the '376 patent, and the Seventh Cause of Action is infringement of the '500 patent. Each alleges infringement under § 271(e)(2)(A) by submission of the ANDA with a Paragraph IV certification. Each alleges, on information and belief, that the ANDA products infringe at least claim 1 of that patent, literally or under the doctrine of equivalents, and each seeks relief under § 271(e)(4) and, if appropriate, attorneys' fees under § 285. The Fourth Cause of Action, the Sixth Cause of Action, and the Eighth Cause of Action seek declaratory judgments of infringement of the '749, '376, and '500 patents. Each alleges, on information and belief, that if the ANDA is approved, Sun and its affiliates will directly infringe under at least § 271(a), literally or under the doctrine of equivalents, and will contribute to or induce infringement under § 271(b) and (c). Each alleges that the case is exceptional and that Pfizer is entitled to attorneys' fees under § 285.
The relief sought
The prayer asks for a judgment that Sun infringes one or more claims of the asserted patents under 35 U.S.C. § 271(e)(2)(A). It asks for a declaratory judgment that Sun's manufacture, use, offer for sale, sale, and/or importation of the ANDA products will directly infringe under at least § 271(a), and a declaratory judgment that Sun's manufacture, use, offer for sale, or sale of the ANDA products in the United States, or importation, will induce and/or contribute to infringement under §§ 271(b) and/or (c). It asks for a permanent injunction under §§ 271(e)(4)(B) and/or 283 against Sun, its affiliates and subsidiaries, and all persons or entities acting in concert with Sun, restraining and enjoining them from commercially manufacturing, using, offering for sale, selling, or importing any product that infringes the asserted patents, including the ANDA products. It asks for an order under § 271(e)(4)(A) that the effective date of any FDA approval of ANDA No. 219998 be no earlier than the latest expiration date of the asserted patents, or any later expiration of any patent term extension or exclusivity to which Pfizer is or becomes entitled. It asks for a declaration under 28 U.S.C. § 2201 that if Sun, its officers, agents, servants, employees, licensees, representatives, and attorneys, and any other persons acting or attempting to act in active concert or participation with Sun or acting on its behalf, engages in the commercial manufacture, use, offer for sale, sale, and/or importation of the product described in the ANDA, that conduct will constitute direct and/or indirect infringement. It asks for damages or other relief under § 271(e)(4)(C), awarded to Pfizer with prejudgment interest, to the extent Sun commercially manufactures, uses, provides, offers to sell, or sells in the United States, or imports, any product that infringes or induces or contributes to infringement before expiration, including any later patent term extension or exclusivity to which Pfizer is or becomes entitled. It asks for a judgment that the case is exceptional and for attorneys' fees under §§ 271(e)(4) and 285, for costs and expenses, and for other relief the court deems just and proper.
What to watch next
Watch for an answer or a Rule 12 motion. The case can end at any time, including by settlement or voluntary dismissal.